(C) Reuters. Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux
(Reuters) – Mylan NV (O:MYL) reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.
The drugmaker reported net earnings of $39.4 million, or 8 cents per share, in the three months ended June 30, compared to a loss of $168.5 million, or 33 cents per share, a year earlier.
Total revenue of the company, whose merger with Pfizer Inc’s (N:PFE) off-patent branded drugs unit has been delayed by the pandemic, fell to $2.73 billion from $2.85 billion.
Mylan posts quarterly profit compared to year-earlier loss
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.